<乌鸦传媒>Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients Oct 12, 2023
<乌鸦传媒>Primary Care Intervention Improved Follow-Up of Abnormal Cancer Screening Results Follow-up testing within 120 days was improved with EHR reminders, patient outreach, navigation Oct 10, 2023
<乌鸦传媒>Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel But聽agency doesn't plan to immediately push for KRAS inhibitor's withdrawal Oct 05, 2023
<乌鸦传媒>Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? Detectable circulating tumor DNA before radiotherapy linked with worse survival Oct 05, 2023
<乌鸦传媒>FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC Reviewers see potentially tiny PFS benefit with sotorasib, raise concerns over "systemic bias" Oct 04, 2023
<乌鸦传媒>The White House Cancer Moonshot Is a Dud We're failing to take simple steps to reduce one of the biggest causes of cancer Sep 22, 2023
<乌鸦传媒>Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancer Threefold risk reduction with enoxaparin in high-risk gastrointestinal, lung cancers Sep 21, 2023
<乌鸦传媒>Individualized SABR for Lung Tumors Yields Low Recurrence Rates Strategy also results in low rates of severe toxic effects Sep 14, 2023
<乌鸦传媒>IMRT Best for Locally Advanced NSCLC, Study Suggests Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT Sep 13, 2023
<乌鸦传媒>Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC Confirmed responses reached 29.8% in heavily pretreated patients Sep 13, 2023
<乌鸦传媒>Study Questions Use of Aggressive Surgery in Early Mesothelioma Randomized data suggest surgery increases risk of death by 28% over first 42 months Sep 12, 2023
<乌鸦传媒>Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone Sep 12, 2023
<乌鸦传媒>First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
<乌鸦传媒>How the Chemotherapy Shortage Is Affecting Frontline Clinicians "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
<乌鸦传媒>Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Types More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib Aug 23, 2023
<乌鸦传媒>Removing Race-Corrected Pulmonary Function Tests May Alter Lung Cancer Care Path to eliminating these tests, while crucial, will be challenging, researchers say Aug 16, 2023
<乌鸦传媒>Multi-Cancer Early Detection: 20th-Century Fiction Becomes Reality These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
<乌鸦传媒>Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLC Approach is "potentially practice-changing," editorialist says Jul 20, 2023
<乌鸦传媒>Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Use But PFS, OS longer with ICIs plus chemotherapy among patients treated with PPIs Jul 11, 2023
<乌鸦传媒>Hooray! A Clearer Estimate of Your Risk for Death Is Here Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
<乌鸦传媒>TTFields Therapy Yields OS Improvement in Second-Line NSCLC However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
<乌鸦传媒>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
<乌鸦传媒>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
<乌鸦传媒>New Data in NSCLC Bolster Support for Perioperative Immunotherapy EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
<乌鸦传媒>New Standard in Operable EGFR-Positive Lung Cancer "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
<乌鸦传媒>Lung Cancer Screening Results Influence Follow-Up Adherence Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
<乌鸦传媒>'Potential' New Option for Operable NSCLC Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
<乌鸦传媒>FDA Allows Lower Risk Designation for Snuff Product The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
<乌鸦传媒>AI Tool Forecasts Lung Cancer Risk From a Single CT Scan Experts give high marks to performance of "Sybil" in predicting disease over 6 years Feb 07, 2023
<乌鸦传媒>Risk Model-Based Lung Cancer Screening More Cost-Effective Than USPSTF Recs Risk prediction models more sensitive than age-, smoking history-based methods Feb 07, 2023
<乌鸦传媒>Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer A majority of patients obtained disease control with tarlatamab; responses proved durable Feb 01, 2023
<乌鸦传媒>Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patients Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
<乌鸦传媒>Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
<乌鸦传媒>Lung Cancer Survival High for Patients With Early, Screen-Detected Tumors Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate Nov 28, 2022
<乌鸦传媒>Lung Cancer Screening Programs Hit the Mark on Eligibility Criteria However, adherence to follow-up screening is "suboptimal" Oct 10, 2022
<乌鸦传媒>FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
<乌鸦传媒>KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
<乌鸦传媒>Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
<乌鸦传媒>Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
<乌鸦传媒>Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
